Top

Published in:

01-05-2009 | Epidemiology

Screening caused rising incidence rates of ductal carcinoma in situ of the breast

Authors: L. N. van Steenbergen, A. C. Voogd, J. A. Roukema, W. J. Louwman, L. E. M. Duijm, J. W. W. Coebergh, L. V. van de Poll-Franse

Published in: Breast Cancer Research and Treatment | Issue 1/2009

Abstract

The purpose of this study was to examine trends in incidence and detection of ductal carcinoma in situ (DCIS) of the breast in southern Netherlands in the period 1984–2006 and assess the effect of mass screening. All patients with primary DCIS registered between 1984 and 2006 in the population-based Eindhoven Cancer Registry were included (n = 1,767). These data were linked to data from the population-based screening programme. The incidence of DCIS of the breast increased from 3/100,000 to almost 34/100,000 person-years in women aged 50–69 years in southern Netherlands since 1984. Mass screening was responsible for this increase. A stable 60% of DCIS was screen-detected. Over 11% of breast cancer patients have DCIS. In conclusion, the incidence of DCIS increased markedly in southern Netherlands with a clear effect of mammography screening since 1992.

Louwman WJ, Voogd AC, van Dijck JA et al (2008) On the rising trends of incidence and prognosis for breast cancer patients diagnosed 1975–2004: a long-term population-based study in southeastern Netherlands. Cancer Causes Control 19(1):97–106. doi:10.1007/s10552-007-9075-8 PubMedCrossRef

Welch HG, Black WC (1997) Using autopsy series to estimate the disease “reservoir” for ductal carcinoma in situ of the breast: how much more breast cancer can we find? Ann Intern Med 127(11):1023–1028PubMed

Ernster VL, Ballard-Barbash R, Barlow WE et al (2002) Detection of ductal carcinoma in situ in women undergoing screening mammography. J Natl Cancer Inst 94(20):1546–1554PubMed

Barchielli A, Federico M, De Lisi V et al (2005) In situ breast cancer: incidence trend and organised screening programmes in Italy. Eur J Cancer 41(7):1045–1050PubMedCrossRef

Fracheboud J, Otto SJ, van Dijck JA et al (2004) Decreased rates of advanced breast cancer due to mammography screening in The Netherlands. Br J Cancer 91(5):861–867PubMed

Stichting Bevolkingsonderzoek Borstkanker Zuid (2006) Jaarverslag 2006 Stichting Bevolkingsonderzoek Borstkanker Zuid

Otten JD, Karssemeijer N, Hendriks JH et al (2005) Effect of recall rate on earlier screen detection of breast cancers based on the Dutch performance indicators. J Natl Cancer Inst 97(10):748–754PubMedCrossRef

Brekelmans CT, Seynaeve C, Bartels CC et al (2001) Effectiveness of breast cancer surveillance in BRCA1/2 gene mutation carriers and women with high familial risk. J Clin Oncol 19(4):924–930PubMed

Ernster VL, Barclay J, Kerlikowske K et al (1996) Incidence of and treatment for ductal carcinoma in situ of the breast. JAMA 275(12):913–918. doi:10.1001/jama.275.12.913 PubMedCrossRef

10.

Levi F, Te VC, Randimbison L et al (1997) Trends of in situ carcinoma of the breast in Vaud, Switzerland. Eur J Cancer 33(6):903–906. doi:10.1016/S0959-8049(97) 00048-8 PubMedCrossRef

11.

Zheng T, Holford TR, Chen Y et al (1997) Time trend of female breast carcinoma in situ by race and histology in Connecticut, USA. Eur J Cancer 33(1):96–100. doi:10.1016/S0959-8049(96) 00371-1 PubMedCrossRef

12.

Choi WS, Parker BA, Pierce JP et al (1996) Regional differences in the incidence and treatment of carcinoma in situ of the breast. Cancer Epidemiol Biomarkers Prev 5(4):317–320PubMed

13.

Soerjomataram I, Coebergh JW, Louwman MW et al (2007) Does the decrease in hormone replacement therapy also affect breast cancer risk in the Netherlands? J Clin Oncol 25(31):5038–5039. doi:10.1200/JCO.2007.13.7281 (author reply 5039–5040)

Title: Screening caused rising incidence rates of ductal carcinoma in situ of the breast
Authors: L. N. van Steenbergen
A. C. Voogd
J. A. Roukema
W. J. Louwman
L. E. M. Duijm
J. W. W. Coebergh
L. V. van de Poll-Franse
Publication date: 01-05-2009
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 1/2009
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-008-0067-5

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2009

Mutation analysis of BRIP1/BACH1 in BRCA1/BRCA2 negative Chinese women with early onset breast cancer or affected relatives

Disruption of estrogen receptor α-p53 interaction in breast tumors: a novel mechanism underlying the anti-tumor effect of radiation therapy

Circulating steroid hormone concentrations in postmenopausal women in relation to body size and composition

Do cell surface trafficking impairments account for variable cell surface sodium iodide symporter levels in breast cancer?

Overweight, obesity and breast cancer prognosis: optimal body size indicator cut-points

A common Greenlandic Inuit BRCA1 RING domain founder mutation

Keynote webinar | Spotlight on antibody–drug conjugates in cancer